Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients.
Seree-Aphinan C, Ratanapokasatit Y, Suchonwanit P, Rattanakaemakorn P, O-Charoen P, Pisitkun P, Suangtamai T, Setthaudom C, Chirasuthat S, Chanprapaph K. Seree-Aphinan C, et al. Among authors: ratanapokasatit y. Front Immunol. 2023 Mar 15;14:1138765. doi: 10.3389/fimmu.2023.1138765. eCollection 2023. Front Immunol. 2023. PMID: 37006291 Free PMC article.
A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases.
Chanprapaph K, Seree-Aphinan C, Rattanakaemakorn P, Pomsoong C, Ratanapokasatit Y, Setthaudom C, Thitithanyanont A, Suriyo A, Suangtamai T, Suchonwanit P; COVIDVAC-DERM study group. Chanprapaph K, et al. Among authors: ratanapokasatit y. Br J Dermatol. 2023 Feb 10;188(2):268-277. doi: 10.1093/bjd/ljac045. Br J Dermatol. 2023. PMID: 36637102
Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants.
Seree-Aphinan C, Chanprapaph K, Rattanakaemakorn P, Setthaudom C, Suangtamai T, Pomsoong C, Ratanapokasatit Y, Suchonwanit P. Seree-Aphinan C, et al. Among authors: ratanapokasatit y. Front Med (Lausanne). 2021 Dec 8;8:769845. doi: 10.3389/fmed.2021.769845. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34957149 Free PMC article.
Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial.
Seree-Aphinan C, Rattanakaemakorn P, Suchonwanit P, Thadanipon K, Ratanapokasatit Y, Yongpisarn T, Malathum K, Simaroj P, Setthaudom C, Lohjai O, Tanrattanakorn S, Chanprapaph K; COVIDVAC-DERM Study Group. Seree-Aphinan C, et al. Among authors: ratanapokasatit y. Vaccines (Basel). 2024 Jan 11;12(1):73. doi: 10.3390/vaccines12010073. Vaccines (Basel). 2024. PMID: 38250886 Free PMC article.